Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.4%

110 terminated/withdrawn out of 672 trials

Success Rate

75.5%

-11.0% vs industry average

Late-Stage Pipeline

6%

40 trials in Phase 3/4

Results Transparency

47%

160 of 339 completed trials have results

Key Signals

110 recruiting160 with results56 terminated54 withdrawn

Enrollment Performance

Analytics

N/A
287(55.2%)
Phase 2
118(22.7%)
Phase 1
63(12.1%)
Phase 3
20(3.8%)
Phase 4
20(3.8%)
Early Phase 1
12(2.3%)
520Total
N/A(287)
Phase 2(118)
Phase 1(63)
Phase 3(20)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (672)

Showing 20 of 672 trials
NCT07335328Phase 1Not Yet Recruiting

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Role: lead

NCT07643428Phase 2Not Yet Recruiting

Cancer Lipidome Adaptation and Resculping Through Omega-3 PUFAs in Breast Tumors

Role: lead

NCT06050707Phase 2Recruiting

MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach

Role: collaborator

NCT04924322Phase 2Recruiting

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

Role: collaborator

NCT04098666Phase 2Active Not Recruiting

Metformin in Alzheimer's Dementia Prevention

Role: collaborator

NCT02098863Recruiting

Sickle Cell Clinical Research and Intervention Program

Role: collaborator

NCT02400190Not ApplicableActive Not Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Role: collaborator

NCT07610642Not ApplicableNot Yet Recruiting

Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers

Role: lead

NCT03783091Phase 2Completed

A Trial of Vitamin B12 in Septic Shock

Role: lead

NCT02774746Not ApplicableRecruiting

Gastroschisis Outcomes of Delivery (GOOD) Study

Role: lead

NCT02177292Not ApplicableActive Not Recruiting

High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)

Role: lead

NCT05674825Phase 1Recruiting

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

Role: lead

NCT06681935Recruiting

Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery

Role: lead

NCT06320054Not ApplicableActive Not Recruiting

Preventing Obstetric Complications With Dietary Intervention

Role: lead

NCT07013565Phase 2Recruiting

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Role: collaborator

NCT05976555Phase 1Not Yet Recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Role: lead

NCT05032820Phase 2Completed

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Role: lead

NCT07274527Not ApplicableRecruiting

Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure

Role: lead

NCT07594886Active Not Recruiting

Left Atrial Pressure-Guided Heart Failure Optimization During Atrial Fibrillation Ablation (LAP AF-HF)

Role: lead

NCT05794880Not ApplicableRecruiting

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Role: lead